C4 Therapeutics, Inc. Accretion (Amortization) of Discounts and Premiums, Investments
C4 Therapeutics, Inc. (CCCC) reported Accretion (Amortization) of Discounts and Premiums, Investments of $1.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-11
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $186.00K, a 67.99% decline year-over-year.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $1.09M, a 39.08% increase year-over-year.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $863.00K, a 20.17% decline year-over-year.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $515.00K, a 62.82% decline year-over-year.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $2.74M, a 49.18% decline from fiscal 2024.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $5.40M, a 42.60% increase from fiscal 2023.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $3.78M.
- C4 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was -$714.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.27M 10-Q · filed 2026-08-11 | $2.14M derived: sum of 3 quarters · filed 2026-08-11 | $2.65M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.09M 10-Q · filed 2026-05-12 | $1.95M derived: sum of 2 quarters · filed 2026-05-12 | $2.47M derived: sum of 3 quarters · filed 2026-05-12 | $3.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $863.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.38M derived: sum of 2 quarters · filed 2026-02-26 | $1.96M derived: sum of 3 quarters · filed 2026-08-11 | $2.74M 10-K · filed 2026-02-26 |
| 2025-09-30 | $515.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.10M derived: sum of 2 quarters · filed 2026-08-11 | $1.88M 10-Q · filed 2025-11-06 | $2.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $581.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.36M 10-Q · filed 2026-08-11 | $2.44M derived: sum of 3 quarters · filed 2026-08-11 | $3.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $783.00K 10-Q · filed 2026-05-12 | $1.86M derived: sum of 2 quarters · filed 2026-05-12 | $3.25M derived: sum of 3 quarters · filed 2026-05-12 | $4.91M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.47M derived: sum of 2 quarters · filed 2026-02-26 | $4.13M derived: sum of 3 quarters · filed 2026-02-26 | $5.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.05M derived: sum of 2 quarters · filed 2025-11-06 | $4.32M 10-Q · filed 2025-11-06 | $5.28M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.93M 10-Q · filed 2025-08-07 | $3.90M derived: sum of 3 quarters · filed 2025-08-07 | $4.99M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.26M 10-Q · filed 2025-05-07 | $2.23M derived: sum of 2 quarters · filed 2025-05-07 | $3.33M derived: sum of 3 quarters · filed 2025-05-07 | $4.40M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $967.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.06M derived: sum of 2 quarters · filed 2025-02-27 | $3.14M derived: sum of 3 quarters · filed 2025-02-27 | $3.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.17M derived: sum of 2 quarters · filed 2024-10-31 | $2.82M 10-Q · filed 2024-10-31 | $3.22M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.72M 10-Q · filed 2024-08-01 | $2.13M derived: sum of 3 quarters · filed 2024-08-01 | $2.09M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $646.00K 10-Q · filed 2024-05-08 | $1.05M derived: sum of 2 quarters · filed 2024-05-08 | $1.01M derived: sum of 3 quarters · filed 2024-05-08 | $596.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $368.00K derived: sum of 2 quarters · filed 2024-02-22 | -$50.00K derived: sum of 3 quarters · filed 2024-02-22 | -$714.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | -$36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$454.00K derived: sum of 2 quarters · filed 2023-11-01 | -$1.12M 10-Q · filed 2023-11-01 | -$1.97M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.08M 10-Q · filed 2023-08-08 | -$1.93M derived: sum of 3 quarters · filed 2023-08-08 | -$2.49M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$664.00K 10-Q · filed 2023-05-04 | -$1.51M derived: sum of 2 quarters · filed 2023-05-04 | -$2.07M derived: sum of 3 quarters · filed 2023-05-04 | -$2.44M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$847.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$1.41M derived: sum of 2 quarters · filed 2023-02-23 | -$1.78M derived: sum of 3 quarters · filed 2023-02-23 | -$1.88M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$558.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$930.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.03M 10-Q · filed 2022-11-03 | -$929.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$474.00K 10-Q · filed 2022-08-04 | -$371.00K derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$102.00K 10-Q · filed 2022-05-05 | $1.00K derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $95.00K 10-K · filed 2022-02-24 | ||
| 2020-09-30 | -$8.00K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | -$334.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |